Can sodium-211 astatide (Na[211At]) be used to treat iodine-negative differentiated thyroid cancer?

Sodium-211 Astatide for Iodine-Refractory Thyroid Cancer

Sodium-211 astatide ([211At]NaAt) is an emerging targeted alpha therapy that shows promising preliminary efficacy and acceptable safety for radioactive iodine-refractory differentiated thyroid cancer, though it remains investigational and is not yet part of standard treatment guidelines.

Current Guideline-Based Standard of Care

The NCCN Guidelines 1 and Chinese management guidelines 2 establish that for clinically progressive or symptomatic RAI-refractory DTC, kinase inhibitors (particularly lenvatinib) remain the preferred systemic therapy, with clinical benefit rates of 50-60% lasting approximately 12-24 months. Traditional cytotoxic chemotherapy like doxorubicin has minimal efficacy and is not recommended 1.

Evidence for Sodium-211 Astatide

Clinical Trial Data

The Alpha-T1 trial 3 represents the first-in-human study demonstrating:

Efficacy outcomes at 6 months:

• 90% achieved stable disease on CT evaluation
• At the 3.5 MBq/kg dose level: 20% complete response, 20% partial response, 40% stable disease, 20% progressive disease
• 40% of patients receiving 3.5 MBq/kg showed >50% reduction in thyroglobulin levels
• One patient showed disappearance of iodine-avid lesions with marked thyroglobulin reduction 4

Safety profile:

• Dose-limiting toxicities occurred at 3.5 MBq/kg: grade 3 hematologic toxicity (lymphopenia/leukopenia) lasting >1 week in 3 of 6 patients
• Other adverse events: salivary gland swelling (predominantly grade 2), xerostomia, nausea, decreased appetite, vomiting
• Well-tolerated overall with manageable toxicity 3

Mechanism and Rationale

Astatine-211 functions as an iodine analogue, accumulating in thyroid cancer cells via the sodium/iodide symporter (NIS) 4, 5. The alpha particles from 211At deliver superior cytotoxic effects compared to beta particles from 131I through:

• Higher linear energy transfer
• DNA double-strand breaks
• Enhanced free radical formation
• Shorter path length allowing more tumor-selective damage 5

Clinical Application Algorithm

For patients with RAI-refractory DTC:

1. First-line systemic therapy: Kinase inhibitors (lenvatinib preferred) per NCCN guidelines 1

2. Consider [211At]NaAt in clinical trial settings when:

   • Progressive disease despite kinase inhibitor therapy
   • Intolerable toxicity from kinase inhibitors
   • Lesions retain NIS expression (iodine uptake capability)
   • Patient meets trial eligibility criteria

3. Optimal dosing based on current evidence: 2.5-3.5 MBq/kg appears most effective, though 3.5 MBq/kg carries higher hematologic toxicity risk 3

4. Administration requirements:

   • Recombinant human TSH stimulation
   • Iodine-restricted diet
   • Single intravenous dose
   • No hospitalization in radiation-controlled area required due to lower radiation exposure compared to 131I 6

Important Caveats and Pitfalls

Key considerations:

• Not FDA-approved: Currently investigational only; the FDA drug label 7 refers to standard sodium acetate, not the astatide formulation
• Production limitations: Requires 30 MeV cyclotron with alpha particle capability; not widely available 4, 6
• Short half-life: 7.2 hours necessitates proximity to production facility 4
• Hematologic monitoring: Close surveillance required for lymphopenia/leukopenia, particularly at higher doses
• Salivary gland toxicity: Similar to RAI therapy; consider sodium perchlorate co-administration to reduce NIS-mediated uptake in normal tissues 8

Toxicity management strategy:

• Grade 3+ adverse reactions require dose reduction or discontinuation 2
• Preventive measures and graded treatment approach essential 2
• Multi-disciplinary evaluation needed for re-administration decisions

Current Clinical Status

Multiple clinical trials are ongoing in Japan (Osaka University) 4, 5 with aims toward drug approval. The therapy shows particular promise for patients who have exhausted standard options, with the potential to significantly alter the treatment landscape for advanced thyroid cancer 4.

The therapeutic window can be broadened by combining sodium ascorbate (to prevent antibody denaturation) with competitive NIS inhibition using sodium perchlorate (to reduce normal organ uptake) 8, though this requires further clinical validation.